MetLife Investment Management LLC Sells 670 Shares of Masimo Co. (NASDAQ:MASI)

MetLife Investment Management LLC reduced its holdings in shares of Masimo Co. (NASDAQ:MASI) by 2.7% during the third quarter, HoldingsChannel.com reports. The fund owned 23,812 shares of the medical equipment provider’s stock after selling 670 shares during the quarter. MetLife Investment Management LLC’s holdings in Masimo were worth $3,175,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Tidal Investments LLC grew its position in shares of Masimo by 14.1% in the first quarter. Tidal Investments LLC now owns 2,179 shares of the medical equipment provider’s stock valued at $320,000 after purchasing an additional 269 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 111 shares during the last quarter. Juncture Wealth Strategies LLC lifted its stake in shares of Masimo by 294.3% in the 2nd quarter. Juncture Wealth Strategies LLC now owns 7,992 shares of the medical equipment provider’s stock valued at $1,007,000 after acquiring an additional 5,965 shares during the last quarter. Cardinal Capital Management increased its holdings in Masimo by 4.6% during the 2nd quarter. Cardinal Capital Management now owns 15,440 shares of the medical equipment provider’s stock valued at $1,945,000 after purchasing an additional 676 shares during the period. Finally, M&G Plc grew its holdings in shares of Masimo by 4.8% during the 2nd quarter. M&G Plc now owns 3,240 shares of the medical equipment provider’s stock worth $408,000 after acquiring an additional 149 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on MASI. BTIG Research upped their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target on the stock in a report on Wednesday, November 6th. Piper Sandler raised their target price on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $167.00.

Masimo Stock Up 1.5 %

Shares of NASDAQ:MASI opened at $174.19 on Wednesday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 12 month low of $96.40 and a 12 month high of $178.27. The company has a 50-day moving average price of $151.13 and a 200 day moving average price of $130.62. The company has a market cap of $9.33 billion, a price-to-earnings ratio of 120.13 and a beta of 1.01.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. During the same quarter last year, the firm earned $0.63 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, equities research analysts predict that Masimo Co. will post 4.03 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.